spacer
home > epc > winter 2009 > degrees of separation
PUBLICATIONS
European Pharmaceutical Contractor

Degrees of Separation

 

What do a shopping centre and a data warehouse have in common? A shopping trip to buy clothes may seem completely different from trying to get data out of your electronic system, but similarities do exist. Have you ever spent time in a changing room unable to find the right shorts despite trying 20 different pairs? And now, think about your (clinical) data warehouse. How much effort do you spend attempting to get your data out of your system and mapping these data from (e)-clinical trials into Study Data Tabulation Model (SDTM), for example, to prepare them for the regulatory submission standard of today? Likewise, having experienced end of season sales, it is not a controlled environment for a data warehouse. Clearing out is necessary both in the real and the digital world, but ultimately you want to have the data stored safely in a controlled manner.

So how does the Biomedical Research Integrated Domain Group (BRIDG) relate to a data warehouse? BRIDG can be the overview map of your (clinical) data warehouse today or in the future. It identifies the relative location where you can access your data in a very organised and controlled environment. In fact, it is more than likely to be the foundation structure of your data warehouse. Why? Because it will be standardised across the industry (it is being submitted for ISO approval), not just a standard of an individual organisation.

Before I discuss the current situation and what is promised in the future, let’s start with a little history.

PAST

The collaboration between Health Level 7 (HL7) and CDISC started in 2001. In 2003, CDISC started to develop the domain analysis model to harmonise their models with HL7. This BRIDG model is distinct from the other CDISC standards as it is a formal model of the shared semantics of regulated bio-medical research. The two major objectives for creating the BRIDG model were:

  • To provide a domain analysis model (DAM) for clinical research that harmonises all of the existing CDISC standards and other relevant protocoldriven clinical research efforts
  • To link clinical research standards with healthcare standards The BRIDG model is the result of four main stakeholders: the CDISC organisation, the HL7 Regulated Clinical Research Information Management (RCRIM) workgroup, the US National Cancer Institute (NCI) and the FDA.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

Banner of CRS on Samedan
spacer

Joerg Dillert is Principal Consultant at Phase Forward with over 18 years’ professional experience both in the pharmaceutical industry and in the application of information technology in industrial scientific research and development. Joerg joined Phase Forward as a Senior Consultant through the merger with Clinsoft Corporation, which he initially joined in 2001. Before joining Clinsoft, Joerg was Head of IT & Data Management at a German CRO for more than nine years. Joerg holds professional qualifications in Electrical & System Engineering as well as in IT-Marketing. In his current role, Joerg supports all the technical aspects of IT system integrations and holds training courses. He has trained more than 500 people in eight years and developed course material on several areas such as XML, Oracle and CDISC.

 

spacer
Joerg Dillert
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

PHASE II & IIa Clinical Trials

21-22 February 2012, Lancaster London Hotel, London

Learn how to overcome challenges in adapting the development process to achieve early Proof of Concept at Informa's 13th Annual Phase I & IIa Clinical Trials event.
More info >>

 
News and Press Releases

Norwich Expands Capabilities for Phase I-III Clinical Trials

Norwich Clinical Services (NCS), a global provider of clinical research services for the pharmaceutical and biotech industries, today announced a significant expansion to its clinical research capabilities in order to meet growing market demand. Primary to the expansion, NCS unveiled a new clinical facility with capabilities to conduct all aspects of Phase I – III clinical trials including pharmacokinetics in healthy volunteers, bio-availability and bio-equivalence studies, drug metabolism studies, dose proportionality studies and multiple dose studies.
More info >>

 

 

Buy Atrovent Online no prescription Buy Symbicort Online no prescription Buy Flovent Online no prescription Buy Flonase Online no prescription Buy Rhinocort Online no prescription Buy Allegra Online no prescription Buy Advair Online no prescription Buy Combivent Online no prescription Buy Astelin Online no prescription Buy Spiriva Online no prescription Buy Ventolin Online no prescription
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement
.